Background-Drug-eluting stents reduce restenosis and reintervention rates but are complicated by stent thrombosis, which may be related to polymer coating. The NEVO sirolimus-eluting coronary stent (NEVO SES) is designed to improve long-term percutaneous coronary intervention safety by combining sirolimus release from reservoirs with bioabsorbable polymer to reduce spatial and temporal polymer exposure. Methods and Results-NEVO ResElution-I was a prospective randomized study in 394 patients with coronary artery disease comparing the NEVO SES with the TAXUS Liberté paclitaxel-eluting coronary stent (TAXUS Liberté PES) stent. The primary end point was in-stent angiographic late loss at 6 months. Six months after percutaneous coronary intervention (PCI), the primary end point favored NEVO SES (0.13Ϯ0.31 mm versus 0.36Ϯ0.48 mm, PϽ0.001 for noninferiority and superiority). The study was not powered for clinical end points and showed no significant difference for NEVO SES versus TAXUS Liberté PES: death: 0.5 versus 1.6%, Pϭ0.36; myocardial infarction: 2.0 versus 2.6%, Pϭ0.75; target lesion revascularization: 1.5 versus 3.2%, Pϭ0.33; major adverse cardiac events: 4.0 versus 7. 4%, Pϭ0.19. No stent thrombosis was observed with NEVO SES, whereas 2 cases occurred in TAXUS Liberté PES. Intravascular ultrasound showed lower percent volume obstruction for NEVO SES (5.5Ϯ11% versus 11.5Ϯ9.7%, Pϭ0.016). Key Words: angioplasty Ⅲ stents Ⅲ restenosis S ince the introduction of the CYPHER sirolimus-eluting coronary stent (CYPHER SES) in 2002, many trials have established that release of sirolimus from a nonerodible polymer significantly reduces restenosis and repeat intervention rates compared with bare-metal and other drug-eluting stents (DES) in a wide variety of clinical settings. [1] [2] [3] [4] [5] However, the clinical benefit of DES may be partially offset by a heightened incidence of late stent thrombosis. 6, 7 Although the causes of late stent thrombosis are multifactorial, permanent polymer surface coatings may play a key role by inciting an inflammatory response because of permanent exposure of the polymer to the vessel wall, even long after the drug has been completely released. 8 Eliminating this risk requires DES developments that reduce both polymer exposure over time Received February 13, 2010; accepted August 23, 2010 Clinical Perspective on p 564
S ince the introduction of the CYPHER sirolimus-eluting coronary stent (CYPHER SES) in 2002, many trials have established that release of sirolimus from a nonerodible polymer significantly reduces restenosis and repeat intervention rates compared with bare-metal and other drug-eluting stents (DES) in a wide variety of clinical settings. [1] [2] [3] [4] [5] However, the clinical benefit of DES may be partially offset by a heightened incidence of late stent thrombosis. 6, 7 Although the causes of late stent thrombosis are multifactorial, permanent polymer surface coatings may play a key role by inciting an inflammatory response because of permanent exposure of the polymer to the vessel wall, even long after the drug has been completely released. 8 Eliminating this risk requires DES developments that reduce both polymer exposure over time and the vessel wall surface in contact with the polymer at any point in time. 9 
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The NEVO sirolimus-eluting coronary stent (NEVO SES) (Cordis Corporation, Bridgewater, NJ) is a new cobaltchromium alloy stent platform that incorporates unique reservoir technology and a bioabsorbable polymer from which sirolimus is released. These design elements, accomplished by creating multiple laser-cut reservoirs and then filling them with a blend of sirolimus and the bioabsorbable polymer, reduce the amount of tissue exposed to the polymer. Absorption of the polymer within approximately 3 months limits the duration of vessel wall exposure to the polymer. Thereafter, only a biologically inert bare-metal platform remains.
The NEVO ResElution-I study, the first clinical trial to evaluate the NEVO SES, is a prospective randomized noninferiority comparison with the TAXUS Liberté paclitaxeleluting coronary stent (TAXUS Liberté PES) (Boston Scientific Corporation, Natick, Mass) using an angiographic primary end point and gathering clinical data.
Methods

Study Design and Patient Selection
Patients from 40 study sites in 9 countries were randomly assigned in a prospective, multicenter, single-blind trial to receive either the NEVO SES or the TAXUS Liberté PES. Patients were eligible (Table 1) if they had stable angina, unstable angina, or silent ischemia with single de novo lesions Յ28 mm in length in arteries with reference vessel diameters ranging from 2.5 to 3.5 mm.
Major exclusion criteria included a PCI within the preceding 30 days, acute myocardial infarction (MI) within the preceding 72 hours, creatinine Ͼ2.0 mg/dL, left ventricular ejection fraction Յ30%, or other significant comorbidities. Angiographic exclusion criteria included left main coronary artery disease, bifurcation lesions, ostial lesions, chronic total occlusions, and lesions with severe calcification or excessive tortuosity.
The study complied with the Declaration of Helsinki, was approved by ethics committees for all centers, and all patients provided written informed consent.
Study Device
The NEVO SES is a novel balloon-expandable cobalt chromium alloy stent ( Figure 1A ) with nondeformable struts 100-m-thick containing multiple laser-cut reservoirs. Each reservoir is individually filled with a bioabsorbable polylactide-coglycolide (PLGA) polymer matrix blended with sirolimus, creating discrete sources for drug elution ( Figure 1B and 1C) . Because polymer and drug are confined to the reservoirs and each reservoir is only partially filled, the stent surface in contact with the vessel wall is completely polymer-free on stent implantation. Ductile hinges protect reservoirs and polymer-drug content from mechanical deformation during stent expansion. The PLGA polymer undergoes complete resorption within approximately 3 months in vivo, leaving only the bare metal stent as a permanent implant (Figure 2 ). PLGA, which has a long history of human use as suture material and in other medical devices, is metabolized to carbon dioxide and water. 10 Sirolimus coronary arterial tissue levels in vivo are similar to those achieved by the CYPHER SES. In vitro testing shows that the NEVO SES has high flexibility and a low crossing profile enhancing deliverability. The high expanded-stent flexibility promotes conformability (Figure 3 ).
Study Procedures
A central randomization system allocated patients on a 1:1 basis to receive a NEVO SES or TAXUS Liberté PES after the lesion was crossed by the guide wire. Random assignment was stratified for diabetes mellitus to prevent imbalance between groups. The first 50 patients in each treatment arm at 14 selected study sites were included in an intravascular ultrasound (IVUS) substudy (Figure 4) . NEVO SES were available in diameters of 2.5, 3.0, and 3.5 mm with lengths of 8, 12, 17, 22, 28 , and 33 mm. TAXUS Liberté PES were available in diameters of 2.5 mm, 3.0 mm, and 3.5 mm (lengths, 8, 12, 16, 20, 24, 28 , and 32 mm). Stents were implanted using standard techniques; predilatation was mandatory. All patients were required to undergo angiographic follow-up at 6 months and clinical follow-up at 30 days, 6 months, and annually for 5 years.
Before stent implantation, patients who were not on a maintenance dose for aspirin or clopidogrel were administered a minimum loading dose of 300 mg of aspirin or clopidogrel. Dual-antiplatelet therapy was mandated for a minimum of 6 months after the procedure with indefinite continuation of aspirin. Periprocedural anticoagulation with heparin or bivalirudin and administration of glycoprotein IIb/IIIa inhibitors was according to local practice. ECGs were recorded at baseline and within 24 hours after the procedure.
Creatine kinase and creatine kinase-MB fraction were measured at baseline, 6 to 12 hours, and 16 to 24 hours after stent implantation.
Outcomes and Data Management
The prespecified primary end point was in-stent late lumen loss (LL) at 6 months measured by quantitative coronary angiography (QCA). Secondary clinical end points included death, MI (defined according to the WHO definition based on creatine kinase and creatine kinase-MB rise), 11 target lesion and target vessel revascularization (TLR, defined as repeat PCI, or coronary artery bypass grafting to the target lesion, target vessel revascularization, defined as repeat PCI or coronary artery bypass grafting of the target vessel) and the composite end points of major adverse cardiac events (death, MI, and TLR), target lesion failure (cardiac death, target vessel-related MI, clinically driven TLR), and stent thrombosis (ST) adjudicated according to the Academic Research Consortium (ARC) classification. 12 Procedural secondary end points included device success (attainment of Ͻ50% in-stent residual stenosis of the target lesion, as measured by QCA, using the assigned device), lesion success (attainment of Ͻ50% residual stenosis of the target lesion, as measured by QCA, using any percutaneous method), and procedure success (attainment of a final lesion success and no in-hospital major adverse cardiac events), as previously described. 13 Secondary angiographic end points included in-stent and insegment binary restenosis and in-stent minimal lumen diameter (MLD). The IVUS end point was percent neointimal volume obstruction, (neointimal volume/stent volumeϫ100). Subgroup analysis according to diabetic status and lesion length was prespecified.
NEVO RES-I is a single-blinded study. The operators knew the treatment assigned, but the patients and staff involved in follow-up did not. Data were entered into electronic case report forms (KIKA Medical, France) and transferred directly to an independent CRO (Harvard Clinical Research Institute, Boston, Mass) for data management and analysis. Study monitors verified all electronic case reports against on-site source data. An independent and blinded clinical events committee adjudicated all deaths, MI, ST, revascularization procedures, and cerebrovascular events. The polymer is completely absorbed within 90 days, leaving only the bare-metal stent platform behind. A, Photographs of NEVO SES explanted at several time points after implantation in porcine coronary arteries. PLGA polymer is evident within the reservoirs at 8, 30, and 60 days but is no longer present at 90 days. B, Drawing shows a crosssectional view of a reservoir. The drugpolymer matrix is contained within the reservoir and slightly recessed. The reservoir is only partially filled, which prevents direct contact between the PLGA polymer and the vessel wall.
Quantitative Coronary Angiography
Coronary angiograms, obtained at baseline, completion of the stenting procedure, and 6-month follow-up were analyzed at Beth Israel Deaconess Medical Center Angiographic Core Laboratory, Boston, Mass, according to standard morphological criteria and a computer-based system using edge detection technique (Medis). Late luminal loss was defined as the difference between the MLD immediately after the procedure and at 6 months. Binary restenosis was defined as a reduction of 50% or more of the luminal diameter in the target lesion. QCA measurements of the target lesion were obtained within the stent ("in-stent") and within the segment ("insegment," including the stented segment and 5 mm of vessel proximally and distally). Qualitative assessment of restenosis patterns used the Mehran classification. 14 
Intravascular Ultrasound
Serial IVUS imaging with motorized pullback was performed after stent implantation and at 6-month follow-up. Quantitative IVUS measurement was performed at an independent blinded IVUS core laboratory (Cardiovascular Core Analysis Laboratory, Stanford University, Stanford, Calif), using commercially available planimetry software (echoPlaque, Indec Systems Inc, Santa Clara, Calif) based on the ACC Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of IVUS. 15 
Quality of Life Assessments
Quality of life (QOL) surveys were planned at baseline, before stenting, and 30 days, 6 months, and 1 year after stenting. The results of this evaluation will be reported in a separate report.
Statistical Analysis
The samples size estimate for the primary end point analysis was based on a noninferiority ⌬ for angiographic late lumen loss of 0.20 mm and a standard deviation of 0.45 mm, typically seen in studies with the TAXUS stent investigating a comparable patient population. 16 -18 Assuming no difference in mean in-stent late loss 
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for both the NEVO SES and the TAXUS Liberté PES and a common standard deviation of 0.45 mm, a sample size of 310 subjects would yield greater than 90% power to demonstrate the noninferiority between 2 groups with a margin of 0.20 mm. Adjustment for up to 20% loss to follow-up resulted in a total sample size of 388.
Patients were analyzed according to the stent to which they were assigned. If the primary end point of noninferiority was achieved, a test of superiority was to be conducted. Secondary end points were analyzed using either a t test for continuous variables or a Fisher exact test for discrete variables. All superiority analyses used a 2-sided ␣ϭ0.05 significance level. A probability value of Ͻ0.05 was considered significant.
The study was not powered for clinical end points such as death, TLR, MI, and ST. 
Role of the Funding Source
Results
Baseline Patient and Lesion Characteristics
A total of 394 patients were enrolled from March to October 2008: 202 were randomly assigned to the NEVO SES and 192 to the TAXUS Liberté PES arm; 100 patients were enrolled in the IVUS substudy (Figure 4) . Baseline patient and lesion characteristics were similar between groups (Table  1) . Many patients had a history of MI (32.2% NEVO SES/26.0% TAXUS Liberté PES) or previous PCI (33.7% NEVO SES/25.0% TAXUS Liberté PES). Lesion and procedural characteristics were balanced between treatment groups with a high rate of B2 and C lesions. Lesion success was 100% in both stent groups, procedural success was 97.5% for NEVO SES and 97.4% for TAXUS Liberté PES, and device success was 99.5% for both.
Angiographic Outcomes at 6 Months
Of the 394 patients enrolled, 1 was treated with a bare-metal stent during index procedure, 4 died, and 7 withdrew from the study. As a result, 382 patients were available for clinical follow-up at 6 months (97.0%). Qualifying 6-month angiograms were available for 352 (89.3%) ( Table 2 ). Late loss was not analyzable in 1 patient. Therefore, the primary end point was analyzed in 351 of 394 (89.0%) of the enrolled patients. The primary end point of in-stent LL was 0.13Ϯ0.31 mm for NEVO SES and 0.36Ϯ0.48 mm for TAXUS Liberté PES, reaching statistical significance for noninferiority (PϽ0.001) and for superiority (PϽ0.001). The results of the Wilcoxon rank-sum test for were consistent with the results of parametric testing on the conclusion of superiority when comparing in stent late loss and percent diameter stenosis at 6 months (PϽ0.0001 for each comparison). NEVO SES was superior to TAXUS Liberté PES in patients with diabetes (nϭ66; LL, 0.17Ϯ0.42 mm and 0.44Ϯ0.55 mm, respectively, Pϭ0.032). In-segment binary restenosis was superior for NEVO SES (3.2%; 6/186) over TAXUS Liberté PES (8.4%; 14/166) (Pϭ0.040). In-segment binary restenosis was more focal with NEVO SES than TAXUS Liberté PES (NEVO SES: nϭ6, 83.3% Grade IB, 16.7% Grade II; TAXUS Liberté PES: nϭ14, 21.4% Grade IB, 57.1% Grade IC, 14.3% Grade II, and 7.1% Grade III; Pϭ0.05). Angiographic frames from the first patient to receive a NEVO SES are shown in Figure 3 .
IVUS Outcomes at 6 Months
Accounting for patients lost to IVUS follow-up and nonanalyzable images, volumetric IVUS analysis was available in 73 cases (35 NEVO SES; 38 TAXUS Liberté PES). The NEVO SES was superior for the prespecified IVUS end point of percent volume obstruction (NEVO SES, 5.5Ϯ11.0%; TAXUS Liberté PES, 11.5Ϯ9.7%; Pϭ0.016).
Clinical Outcomes
These were available at 6 months ( Table 3) in 382 of 394 patients (97.0%). In both groups, Ͼ97% of patients complied with dual-antiplatelet regimens. There were no significant ‡Diameter stenosis Ͼ50% at follow-up. P values indicate noninferiority of NEVO SES over Taxus Liberté PES.
§This P value indicates superiority of NEVO SES over Taxus Liberté PES (primary end point).
differences in the rates of death, MI, TLR, or major adverse cardiac events (Table 3) , but all differences favored the NEVO SES group.
There was no ST in the NEVO SES group but 2 episodes of ST in the TAXUS Liberté PES group with 1 ARCprobable ST occurred at day 180, causing MI in a patient receiving dual-antiplatelet therapy. The other, an ARCpossible ST occurred at day 101 in a patient also receiving dual-antiplatelet therapy.
Clinical and angiographic outcomes of the diabetic subgroup analysis are given in Table 4 , and a forest plot analysis of other specific subgroups is given in Figure 5 .
Discussion
This study achieved its primary end point, demonstrating that the NEVO SES was noninferior, and in fact superior, to the TAXUS Liberté PES for 6-month angiographic late loss. A similar result was found in the subgroup of diabetic patients and across all lesion lengths and vessel sizes studied. Intravascular ultrasound further supported the superior antirestenotic efficacy of the NEVO SES, demonstrating significantly less percentage volume neointimal obstruction. There was no ST with the NEVO SES, but there were 2 cases in TAXUS Liberté PES. All clinical end points numerically favored the NEVO SES.
The net clinical value of DES, compared with bare-metal stents, lies in the degree to which they reduce the clinical burden of restenosis, offset by a possible elevation in the risk of ST. Efforts to design stents that will optimize this net clinical value are warranted because restenosis prevention and thrombosis provocation are not known to share common 
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mechanisms and are potentially dissociable. NEVO ResElution-I is the first trial to assess the NEVO SES that releases sirolimus from a new local drug-delivery platform concentrating a bioabsorbable polymer-drug blend in dedicated reservoirs instead of using a surface coating. This design may remove a major possible mechanism of DES ST, namely the exposure of the coronary tissue to potentially proinflammatory polymer material. The NEVO SES has been designed to release sirolimus to yield arterial tissue sirolimus concentrations similar to those with the CYPHER SES. It is therefore of interest to compare the design and clinical results of the NEVO ResElution-I study with those of RAVEL 1 and SIRIUS, 2 the 2 early pivotal studies with the CYPHER SES. The percentage of diabetic patients in the NEVO SES arm of ResElution-I is 17.8%, versus 16.0% in RAVEL and 25.0% in SIRIUS. There were 26.2% patients with type C lesions for NEVO SES in this trial, compared with 26% in SIRIUS and 0% in RAVEL. Therefore, ResElution-I investigated more patients of higher complexity and risk for restenosis than RAVEL and was close in composition to the SIRIUS trial population.
Late loss values for the CYPHER SES are well established as ranging from 0.13 to 0.24 mm at 6 months. 19 Because we observed similar in-stent loss for the NEVO SES, the results of the NEVO ResElution-I trial suggest that the antirestenotic efficacy of the NEVO SES is similar to that of the CYPHER SES.
In addition, there was much less variability in distribution of LL measurements with the NEVO SES than with TAXUS Liberté PES. This suggests a more homogenous tissue response to injury and therapy and perhaps a more consistent drug effect throughout the stented segment and between lesions. Possible explanations may include more even distribution of sirolimus than paclitaxel in the arterial vessel because of differences in physicochemical properties, more consistent and homogeneous local drug delivery via reservoirs than from surface coating, more conformable stent design with NEVO SES than TAXUS Liberté PES providing more complete vessel coverage or patient-to-patient variability in response to the permanent polymer of TAXUS Liberté PES compared with the bioresorbable, nonexposed polymer of NEVO SES. Extending this analysis, it is interesting to note that the standard deviation in the LL distribution noted in the NEVO ResElution-I study (0.31 mm) is markedly lower than that of the CYPHER SES arm in the SIRIUS trial (0.48 mm). 2 The relative efficacy of different DES in diabetic patients remains controversial. Studies with angiographic primary end points have consistently demonstrated the superiority of sirolimus eluting over bare metal 20, 21 or paclitaxel-eluting stents 22 and a reduction in target lesion revascularization rates. On the other hand, a heterogeneity analysis of the diabetic subgroup of 4 randomized trials comparing the CYPHER SES with the BX Velocity stent 23 suggested a higher rate of adverse events in patients receiving the CYPHER SES, although this was not confirmed in larger meta-analyses. 5, 24 In the SPIRIT II, 25 III, 26 and IV 27 trials comparing the Xience V everolimus-eluting coronary stent (Xience V EES) (Abbott Vascular, Redwood City, Calif) with the TAXUS PES, although significant reductions in TLR rates were found favoring the Xience V EES, in diabetic subgroups outcomes with TAXUS PES and XIENCE-V EES were similar. 26, 27 Paclitaxel has been postulated to be an effective drug in diabetic patients. 28 For the diabetic subgroup in the present study, in-stent LL was significantly less for NEVO SES (0.17Ϯ0.42 mm) versus TAXUS Liberté PES (0.44Ϯ0.55 mm) (Pϭ0.032), suggesting superior efficacy of NEVO SES in this subgroup.
There was no ST observed in NEVO SES. The 2 late ST events in patients receiving TAXUS Liberté PES occurred despite dual-antiplatelet therapy. Very late ST remains a limitation of DES and has led to the recommendation of prolonged dual-antiplatelet therapy. 6, 7 Pathological studies have suggested inflammation caused by nonresorbable permanent polymers as a potential cause. 8, 9 In the NEVO SES, the bioabsorbable polymer is restricted to the interior of the reservoirs, thereby eliminating contact with the arterial vessel wall. Preclinical studies have shown that polymer is resorbed in approximately 3 months with complete tissue ingrowth into the reservoirs. These distinctive design features of the NEVO SES may limit polymer-induced arterial wall inflammation, reducing the risk of ST and the requirement for prolonged dual-antiplatelet therapy. Long-term follow-up of the NEVO ResElution-I trial and further studies comparing long and short regimens of dual-antiplatelet therapy after implantation of NEVO SES are necessary before definite conclusions can be drawn on this important clinical issue.
Study Limitations
The sample size was calculated to assess a difference in LL, which is a surrogate end point for clinical restenosis. Larger studies are needed to thoroughly assess clinical end points. The TAXUS Liberté PES was chosen as a comparator because it was the most widely used DES when the study was designed. Other trials will be necessary to compare outcomes with the NEVO SES and other DES. Performing the angiographic control at 6 months may not have captured the point of maximum late loss for either stent. However, in previous studies of SES and PES, 6-month outcomes have correlated with later clinical outcomes. 29 Finally, examining outcomes in high-risk patients such as those with acute MI, multivessel coronary disease, or left main coronary artery stenosis will require dedicated trials.
Conclusion
In this large, prospective, first-in-human study randomly assigning 394 patients with single de novo native coronary lesions, the NEVO SES proved superior to TAXUS Liberté for the primary end point of in-stent LL after 6 months. No stent thrombosis occurred in the NEVO SES group. The NEVO SES may offer a significant therapeutic advance, mitigating thrombosis risk without compromising antirestenotic efficacy.
